Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
Open Access
- 11 March 2019
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 7 (1), 18
- https://doi.org/10.3390/biomedicines7010018
Abstract
Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25 blockade reduces IL-2 consumption by effector T cells, it increases IL-2 bioavailability allowing for greater interaction with the intermediate-affinity IL-2R, and therefore drives the expansion of CD56bright natural killer (NK) cells. Furthermore, there appears to be a direct correlation between CD56bright NK cell expansion and DAC HYP efficacy in reducing relapses and MRI evidence of disease activity in patients with RMS in phase II and phase III double-blind, placebo- and active comparator-controlled trials. Therapeutic efficacy was maintained during open-label extension studies. However, treatment was associated with an increased risk of rare adverse events, including cutaneous inflammation, autoimmune hepatitis, central nervous system Drug Reaction with Eosinophilia Systemic Symptoms (DRESS) syndrome, and autoimmune Glial Fibrillary Acidic Protein (GFAP) alpha immunoglobulin-associated encephalitis. As a result, DAC HYP was removed from clinical use in 2018. The lingering importance of DAC is that its use led to a deeper understanding of the underappreciated role of innate immunity in the potential treatment of autoimmune disease.Keywords
This publication has 83 references indexed in Scilit:
- A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapyNature Medicine, 2011
- An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK CellsThe Journal of Immunology, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple SclerosisArchives of Neurology, 2009
- Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple SclerosisArchives of Neurology, 2009
- Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cellsJournal of Leukocyte Biology, 2008
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2006
- Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation1Transplantation, 2003
- lnterleukin-2 programs mouse αβ T lymphocytes for apoptosisNature, 1991
- THE MULTI-SUBUNIT INTERLEUKIN-2 RECEPTORAnnual Review of Biochemistry, 1989